Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

Welcome to the International Journal of Biological Markers, a distinguished publication under SAGE Publications Ltd that has been a vital resource in the fields of Cancer Research, Clinical Biochemistry, Oncology, and Pathology and Forensic Medicine since its inception in 1986. With a commitment to disseminating high-quality research, the journal enjoys a robust impact highlighted by its Q2 and Q3 rankings across multiple categories in 2023, as evidenced by its Scopus rankings placing it in respectable percentiles. Based in Italy, this journal serves a global audience of researchers, clinicians, and students eager to keep abreast of the latest discoveries involving biological markers and their applications in medicine. Emphasizing rigorous peer review and scholarly integrity, the International Journal of Biological Markers plays a crucial role in advancing knowledge that can significantly impact clinical practices and enhance patient care.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

African Journal of Urology (ISSN: 1110-5704, E-ISSN: 1961-9987) is a leading scholarly publication in the field of urology, published by SPRINGER from the United Kingdom. Since adopting an open access model in 2012, this journal has aimed to increase the visibility and dissemination of vital research findings across the African continent and beyond. With a current impact factor and significant standing, as denoted by its Q3 ranking in Urology for 2023, it serves as an essential platform for clinicians, researchers, and students alike. The journal's scope encapsulates all aspects of urology, fostering advancements in both clinical practices and innovative research while specifically addressing healthcare challenges relevant to African populations. As part of its commitment to accessibility and academic excellence, the journal offers full open access to its content, allowing for a broad readership and engagement with cutting-edge studies. Engage with the African Journal of Urology to contribute to and stay informed about vital developments in urological science.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is a pivotal publication in the field of gynecological oncology, dedicated to advancing research and clinical practices. Established in 1980 and published by MRE PRESS, this journal serves as a platform for disseminating high-quality research, reviews, and case studies pertaining to the diagnosis and treatment of gynecological cancers. Although the journal currently operates without an open access option, it remains a valuable resource for professionals seeking to stay abreast of the latest developments and findings within the field. The journal is indexed in both Scopus and other reputable databases, contributing significantly to the ongoing discourse in medicine with a particular focus on obstetrics, gynecology, and oncology, although it has seen a discontinuation in coverage by Scopus post-2021. With an emphasis on rigorous peer-review and scholarly integrity, the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY continues to play an essential role in fostering knowledge and innovation among researchers, clinicians, and students committed to improving patient outcomes in gynecological health.

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Ceska Gynekologie-Czech Gynaecology, ISSN 1210-7832, is a prominent journal in the field of obstetrics and gynecology, published by the esteemed NAKLADATELSKE STREDISKO C L S J E PURKYNE in the Czech Republic. Since its inception in 1959, this journal has served as a vital resource for researchers, practitioners, and students by disseminating high-quality research and insights pertinent to women's health. The journal is currently ranked in the Q3 category for Obstetrics and Gynecology, reflecting its respected position within the academic community, despite its Scopus ranking of #161 out of 209 in the medical field. Ceska Gynekologie offers a platform for sharing innovative clinical practices, research advancements, and educational resources, contributing significantly to the advancement of gynecological care. With a commitment to fostering professional knowledge and practice, this journal remains an essential tool for those engaged in the intricate world of women's health.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.